CM 4612

Drug Profile

CM 4612

Alternative Names: CM-4612; CM-ADHD; CM-AT; CM-PK

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator CureMark LLC
  • Developer Curemark
  • Class Enzymes
  • Mechanism of Action Enzyme modulators; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Autistic disorder
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Autistic disorder
  • Preclinical Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 01 May 2015 Curemark initiates enrolment in a phase III trial for Autistic (In children) disorder in USA (NCT02410902)
  • 04 Nov 2013 Preregistration for Autistic disorder (in children) in USA (PO)
  • 08 Oct 2013 CM 4612 is still in phase III trials for Autistic disorder (in children)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top